Supplements
新型コロナウイルスの感染予防が気になり、サプリを調べてみました。PubMedで2つのreviewがヒットし、一つがこれです。ビタミンDが有効らしいです。日本人のデータではインフルエンザワクチンを打っていない子供ではビタミンDの効果があるのに、インフルエンザワクチンを打った子供ではその効果が消えているのでワクチンと同等の効果があるようです。冬は日光が不足し、その関係でビタミンDが不足し、インフルエンザにかかりやすくなるという論理になります。寒いからインフルエンザにかかるのではない可能性があります。新型コロナウイルスでも同様らしいので部屋に籠らず野外に出かけて定期的に日光にあたってください。不可能であればビタミンDのサプリを飲んで下さい。
--------------------------------------------------------------------------
インフルエンザやCOVID-19のリスクがある人々は、10,000 IU / dのビタミンDの摂取を検討することをお勧めします。血清25（OH）D濃度を上げるためのビタミンDの補給は、病院関連の感染を減らすのに役立ちます。最近のレビューでは、COVID-19のリスクと重症度を軽減するために、50,000 IUカプセルに200,000〜300,000 IUのビタミンD負荷量を使用することが提案されています。 ビタミンDサプリメントを服用する場合は、マグネシウムサプリメントをお勧めします。
To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/d of vitamin D. Vitamin D supplementation to raise serum 25(OH)D concentrations can help reduce hospital-associated infections . A recent review suggested using vitamin D loading doses of 200,000–300,000 IU in 50,000-IU capsules to reduce the risk and severity of COVID-19. Magnesium supplementation is recommended when taking vitamin D supplements.
Nutrients. 2020 Apr 2;12(4). pii: E988. doi: 10.3390/nu12040988.
Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths.
Grant WB1, Lahore H2, McDonnell SL3, Baggerly CA3, French CB3, Aliano JL3, Bhattoa HP4.
The world is in the grip of the COVID-19 pandemic. Public health measures that can reduce the risk of infection and death in addition to quarantines are desperately needed. This article reviews the roles of vitamin D in reducing the risk of respiratory tract infections, knowledge about the epidemiology of influenza and COVID-19, and how vitamin D supplementation might be a useful measure to reduce risk. Through several mechanisms, vitamin D can reduce risk of infections. Those mechanisms include inducing cathelicidins and defensins that can lower viral replication rates and reducing concentrations of pro-inflammatory cytokines that produce the inflammation that injures the lining of the lungs, leading to pneumonia, as well as increasing concentrations of anti-inflammatory cytokines. Several observational studies and clinical trials reported that vitamin D supplementation reduced the risk of influenza, whereas others did not. Evidence supporting the role of vitamin D in reducing risk of COVID-19 includes that the outbreak occurred in winter, a time when 25-hydroxyvitamin D (25(OH)D) concentrations are lowest; that the number of cases in the Southern Hemisphere near the end of summer are low; that vitamin D deficiency has been found to contribute to acute respiratory distress syndrome; and that case-fatality rates increase with age and with chronic disease comorbidity, both of which are associated with lower 25(OH)D concentration. To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/d of vitamin D3 for a few weeks to rapidly raise 25(OH)D concentrations, followed by 5000 IU/d. The goal should be to raise 25(OH)D concentrations above 40-60 ng/mL (100-150 nmol/L). For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful. Randomized controlled trials and large population studies should be conducted to evaluate these recommendations.